These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 7746278)

  • 1. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
    Lelièvre S; Larsen AK
    Cancer Res; 1994 Aug; 54(15):3993-7. PubMed ID: 8033129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
    Dereuddre S; Delaporte C; Jacquemin-Sablon A
    Cancer Res; 1997 Oct; 57(19):4301-8. PubMed ID: 9331091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cellular resistance to DNA-topoisomerase II inhibitors].
    Jacquemin-Sablon A; Bojanowski K; Casabianca-Pignède MR; Crémier S; Delaporte C; Khelifa T; Markovits J; René B; Saucier JM; Larsen AK
    Bull Cancer; 1994 May; 81(5):381-5. PubMed ID: 7749214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
    Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A
    Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
    Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
    Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.